Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms

Rhea-AI Filing Summary

VERAXA Biotech AG reported that it has strengthened its intellectual property around its BiTAC cancer therapy platforms. In the first half of 2026, the company filed initial patent applications for its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) technologies and related therapeutic programs, while previously granted auxiliary technology patents have cleared their opposition period.

VERAXA now has more than 50 granted owned or exclusively licensed patents in 14 countries, spread across 26 patent families, and expects recently filed applications, once granted, to protect its core technology suite through at least 2047. The BiTAC approach uses dual-component constructs and click-chemistry-based "click-to-release" payload activation to enhance tumor selectivity, safety, and manufacturability of next-generation antibody-based therapies.

Key Figures

Granted patents: more than 50 granted patents Countries covered: 14 countries Patent families: 26 patent families +2 more

5 metrics

Granted patents more than 50 granted patents Owned or exclusively licensed as part of VERAXA’s portfolio

Countries covered 14 countries Jurisdictions where VERAXA holds granted patents

Patent families 26 patent families Families encompassing VERAXA’s granted patents

Expected protection horizon through at least 2047 Expected term for core technology suite once recent applications are granted

Reporting period for first BiTAC applications first half of 2026 Timeframe when first BiTAC-related patent applications were filed

Key Terms

bispecific T cell engager, antibody-drug-conjugate, Bi-targeted Tumor-Associated Cytotoxicity, click-to-release, +1 more

5 terms

bispecific T cell engager medical

"including bispecific T cell engagers, bispecific ADCs and other innovative formats"

A bispecific T cell engager is a lab-made protein that acts like a matchmaker between a cancer cell and a patient's immune killer cell (T cell), attaching to both so the T cell can recognize and destroy the cancer cell. For investors, these drugs matter because they can produce powerful, targeted effects that may lead to big clinical and commercial wins, but they also carry high development, safety and manufacturing risks that make outcomes binary and value volatile.

antibody-drug-conjugate medical

"its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) platforms"

An antibody-drug-conjugate is a targeted medicine that pairs a disease-seeking antibody with a potent drug so the treatment is delivered directly to affected cells, like a guided missile carrying a warhead to a specific target. For investors it matters because ADCs can offer high-value, precision therapies whose clinical trial results, approvals, manufacturing challenges and pricing decisions can drive big shifts in a drug developer’s revenue and stock value.

Bi-targeted Tumor-Associated Cytotoxicity medical

"through its BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) strategy"

click-to-release technical

"The payload is only released inside the cancer cell through a rapid, highly efficient chemical reaction called ‘click-to-release’."

trans-cyclooctenes (TCOs) technical

"leverages the ultra-fast reaction between trans-cyclooctenes (TCOs) and tetrazines"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/31/2026 - 04:05 PM Accepted by SEC EDGAR 07/31/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What is the main update in VERAXA Biotech (VRXA) July 2026 Form 6-K?

VERAXA Biotech’s July 2026 Form 6-K reports an update to its core patent portfolio. The company filed new BiTAC-TCE and BiTAC-ADC patent applications and highlights that auxiliary technology patents have cleared their opposition period, strengthening protection for its oncology platforms.

How large is VERAXA Biotech’s (VRXA) patent portfolio after the latest update?

VERAXA now reports a portfolio of more than 50 granted owned or exclusively licensed patents. These patents span 14 countries and are organized into 26 patent families, covering its BiTAC platforms and contributing technologies such as click chemistry and conjugation.

How long could VERAXA Biotech’s (VRXA) patents protect its core technologies?

VERAXA states that, once recently filed applications are granted, they are expected to protect its core technology suite through at least 2047. This projected horizon covers its BiTAC-TCE and BiTAC-ADC platforms and related payload and conjugation technologies.

What are VERAXA Biotech’s (VRXA) BiTAC-TCE and BiTAC-ADC platforms?

BiTAC-TCE and BiTAC-ADC are next-generation bispecific T cell engager and antibody-drug-conjugate platforms. Both use dual-component antibody architectures targeting distinct tumor-associated antigens to enhance tumor selectivity and restrict activity to cancer cells expressing defined marker combinations.

How does VERAXA Biotech (VRXA) use click chemistry in its BiTAC-ADC technology?

VERAXA’s BiTAC-ADCs use a “click-to-release” mechanism based on ultra-fast reactions between trans-cyclooctenes (TCOs) and tetrazines. This chemistry aims to release the drug payload only inside cancer cells and avoid premature release during systemic circulation, while also supporting manufacturing efficiencies.

What broader technologies support VERAXA Biotech’s (VRXA) IP strategy?

Beyond BiTAC, VERAXA’s IP covers conjugation, linker, and hydrophilic payload technologies. These are applied across BiTAC and non-BiTAC pipelines, with the goal of improving safety, efficacy, and manufacturability of its antibody-based cancer therapies.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-43342

Veraxa Biotech AG

Talacker 35

8001 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Strengthening of Patent Portfolio

On July 29, 2026, the Veraxa Biotech AG (the “Company”) issued a press release announcing updates to its core patent portfolio.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release dated July 29, 2026

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VERAXA BIOTECH AG
Date: July 31, 2026	By:	/s/ Christoph Antz
	Name:	Christoph Antz
	Title:	Chief Executive Officer

	By:	/s/ Oliver Baumann
	Name:	Oliver Baumann
	Title:	Chairman of the Board of Directors

2

Exhibit 99.1

Press Release

VERAXA Biotech Strengthens Patent Portfolio to Protect Core
Technology Platforms and Product Candidates

First BiTAC^®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including click chemistry and conjugation technology.

ZURICH, SWITZERLAND – July 29, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio. During the first half of 2026, first patent applications were filed to cover the Company’s new generation of technologies including its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) platforms and therapeutic programs derived from them. Additionally, previously granted patents covering auxiliary technology modules have now cleared the opposition period. Overall, VERAXA now has a portfolio of more than 50 granted owned or exclusively licensed patents in 14 countries, which are spread across 26 patent families. Once the recently filed patent applications are granted, they are expected to protect VERAXA’s core technology suite through at least 2047.

“Patentable innovations are at the heart of any biotechnology company, and we are very pleased to provide an update on recent developments. Our IP strategy mirrors the breadth of novel concepts and innovations we are pursuing with regard to our BiTAC-TCE and BiTAC-ADC platforms, novel payload strategies, and the conjugation technologies and click chemistry enabling such therapies,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “Overall, we are building toward a strong IP portfolio protecting our core technology platforms and product candidates.”

VERAXA is reimagining key aspects of bispecific T cell engager (TCE) and antibody-drug-conjugate (ADC) biology through its BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) strategy. This novel approach relies on a dual-component molecular architecture to enhance tumor selectivity and safety via a true “AND-gate” mechanism. For T cell engagers (BiTAC-TCEs), the platform uses two split antibody constructs. Each targets a distinct tumor-associated antigen and carries one half of the T cell binding motif. Only when both precursors bind to the same cancer cell do they form a functional molecule—a mechanism that restricts T cell activity to cells displaying both tumor markers, sparing healthy tissue. For antibody-drug conjugates (BiTAC-ADCs), the technology delivers a systemically inactive prodrug and a cell-impermeable proactivator through two separate antibodies, each targeting a defined tumor-associated antigen. The payload is only released inside the cancer cell through a rapid, highly efficient chemical reaction called ‘click-to-release’. VERAXA’s click chemistry leverages the ultra-fast reaction between trans-cyclooctenes (TCOs) and tetrazines—one of the fastest in nature. The reaction kinetics and other proprietary improvements enable VERAXA to avoid the premature payload release during systemic circulation, as seen with past ADC approaches, and unlock cost savings in BiTAC-ADC manufacturing. In addition, VERAXA applies proprietary conjugation, linker, and hydrophilic payload technologies across its BiTAC and non-BiTAC pipelines, further enhancing the safety, efficacy, and manufacturability of its next-generation therapies.

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

About VERAXA Biotech AG (NASDAQ: VRXA)

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

For regular updates about VERAXA Biotech, visit https://investors.veraxa.com/ or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

BiTAC^® is a registered trademark of VERAXA Biotech GmbH.

Forward-looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements, including as to the ability of the Company’s intellectual property rights to protect its therapeutic candidate portfolio and technology. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations, including with respect to the company’s ability to file future patents, have patents accepted, granted, and subsequently upheld without opposition. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified in the risk factors section of the Company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

2

Contact

VERAXA Biotech AG – Corporate
Christoph Antz, Ph.D.
Chief Executive Officer, Co-Founder
investors@veraxa.com

For Media and Investors – U.S.
Brandon Weiner
ICR Healthcare
VERAXA@icrhealthcare.com

For Media and Investors – EU
Mario Brkulj
investors@veraxa.com

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich

VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

3

Filing Exhibits & Attachments

3 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 14.5 KB
• EX-99 GRAPHIC 79.6 KB
• EX-99 GRAPHIC 13.9 KB